Design, Synthesis, and Preliminary in Vitro and in Vivo Evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): A Novel Potential PET Probe to Image Melanoma Tumors
Authors:
- 17 February 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 20 (3) , 583-590
Abstract
In order to develop a PET radiopharmaceutical to image malignant melanoma, we synthesized N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA). In vitro studies show a high uptake of [18F]-DAFBA by the B16F1 melanoma cells. No significant binding was seen for DAFBA to the sigma-1 and sigma-2 receptors in vitro. The in vivo biodistribution studies performed in normal ICR mice showed a low uptake in the normal tissues followed by further elimination of radioactivity from these tissues with time. The biodistribution studies performed in C57 mice bearing the melanoma tumor xenograft showed a rapid uptake of radioactivity in the tumor that reached a plateau within 30 min postinjection. The F-18 uptake in the tumor was 7.00 ± 2.76, 6.57 ± 1.66, and 5.80 ± 0.98%ID/g at 60, 120, and 180 min, respectively. A steady uptake of radioactivity in the tumor and low uptake in normal tissues resulted in high tumor to normal tissue ratios. For example, at 180 min postinjection, the tumor to tissue ratios were 14.90 ± 6.47, 21.90 ± 4.68, 32.91 ± 6.11, 39.73 ± 11.78, and 6.33 ± 1.9, for the spleen, lungs, muscle, blood, and liver, respectively. The radioactivity rapidly cleared from the blood pool, and it decreased from 0.68 ± 0.21%ID/g at 60 min to 0.13 ± 0.03%ID/g at 180 min. The F-18 uptake in the bones at 60, 120, and 180 min was 0.91 ± 0.27, 0.57 ± 0.32, and 0.17 ± 0.05%ID/g, respectively. This low uptake in the bones reflects its in vivo resistance toward defluorination. A low residual activity in normal tissues and a high tumor uptake signifies the superior imaging potential of this compound. Because of these positive traits, [18F]-DAFBA could help delineate the tumor and its metastases when used for imaging applications. Further in vivo studies are underway to assess the potential of [18F]-DAFBA as a promising PET imaging probe.Keywords
This publication has 39 references indexed in Scilit:
- Peptide-targeted radionuclide therapy for melanomaCritical Reviews in Oncology/Hematology, 2008
- Uptake in melanoma cells of N-(2-diethylaminoethyl)-2-iodobenzamide (BZA2), an imaging agent for melanoma staging: relation to pigmentationNuclear Medicine and Biology, 2005
- In vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide: a potential sigma receptor ligand for SPECT studiesNuclear Medicine and Biology, 2005
- A Role for FDG-PET in the Surgical Management of Stage IV MelanomaAnnals of Surgical Oncology, 2004
- Baseline staging in cutaneous malignant melanomaBritish Journal of Dermatology, 2004
- Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoaffinity labelingEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Synthesis and Characterization of [125I]-N-(N-Benzylpiperidin-4-yl)-4-iodobenzamide, a New .sigma. Receptor Radiopharmaceutical: High-Affinity Binding to MCF-7 Breast Tumor CellsJournal of Medicinal Chemistry, 1994
- Synthesis and preliminary evaluation of para- and meta-[18F]fluorobenzylguanidineNuclear Medicine and Biology, 1994
- Reductive amination of [18F]fluorobenzaldehydes: Radiosyntheses of [2-18F]- and [4-18F]fluorodexetimidesJournal of Labelled Compounds and Radiopharmaceuticals, 1990
- Aryltrimethylammonium trifluoromethanesulfonates as precursors to aryl [18F]fluorides: Improved synthesis of [18F]GBR‐13119Journal of Labelled Compounds and Radiopharmaceuticals, 1989